Timo Grimmer1, Carolin Wutz2, Panagiotis Alexopoulos2, Alexander Drzezga3, Stefan Förster4, Hans Förstl2, Oliver Goldhardt2, Marion Ortner2, Christian Sorg2, Alexander Kurz2. 1. Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany t.grimmer@lrz.tum.de. 2. Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany. 3. Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany; and. 4. Department of Nuclear Medicine, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany.
Abstract
UNLABELLED: Biomarkers of Alzheimer disease (AD) can be imaged in vivo and can be used for diagnostic and prognostic purposes in people with cognitive decline and dementia. Indicators of amyloid deposition such as (11)C-Pittsburgh compound B ((11)C-PiB) PET are primarily used to identify or rule out brain diseases that are associated with amyloid pathology but have also been deployed to forecast the clinical course. Indicators of neuronal metabolism including (18)F-FDG PET demonstrate the localization and severity of neuronal dysfunction and are valuable for differential diagnosis and for predicting the progression from mild cognitive impairment (MCI) to dementia. It is a matter of debate whether to analyze these images visually or using automated techniques. Therefore, we compared the usefulness of both imaging methods and both analyzing strategies to predict dementia due to AD. METHODS: In MCI participants, a baseline examination, including clinical and imaging assessments, and a clinical follow-up examination after a planned interval of 24 mo were performed. RESULTS: Of 28 MCI patients, 9 developed dementia due to AD, 2 developed frontotemporal dementia, and 1 developed moderate dementia of unknown etiology. The positive and negative predictive values and the accuracy of visual and fully automated analyses of (11)C-PiB for the prediction of progression to dementia due to AD were 0.50, 1.00, and 0.68, respectively, for the visual and 0.53, 1.00, and 0.71, respectively, for the automated analyses. Positive predictive value, negative predictive value, and accuracy of fully automated analyses of (18)F-FDG PET were 0.37, 0.78, and 0.50, respectively. Results of visual analyses were highly variable between raters but were superior to automated analyses. CONCLUSION: Both (18)F-FDG and (11)C-PiB imaging appear to be of limited use for predicting the progression from MCI to dementia due to AD in short-term follow-up, irrespective of the strategy of analysis. On the other hand, amyloid PET is extremely useful to rule out underlying AD. The findings of the present study favor a fully automated method of analysis for (11)C-PiB assessments and a visual analysis by experts for (18)F-FDG assessments.
UNLABELLED: Biomarkers of Alzheimer disease (AD) can be imaged in vivo and can be used for diagnostic and prognostic purposes in people with cognitive decline and dementia. Indicators of amyloid deposition such as (11)C-Pittsburgh compound B ((11)C-PiB) PET are primarily used to identify or rule out brain diseases that are associated with amyloid pathology but have also been deployed to forecast the clinical course. Indicators of neuronal metabolism including (18)F-FDG PET demonstrate the localization and severity of neuronal dysfunction and are valuable for differential diagnosis and for predicting the progression from mild cognitive impairment (MCI) to dementia. It is a matter of debate whether to analyze these images visually or using automated techniques. Therefore, we compared the usefulness of both imaging methods and both analyzing strategies to predict dementia due to AD. METHODS: In MCI participants, a baseline examination, including clinical and imaging assessments, and a clinical follow-up examination after a planned interval of 24 mo were performed. RESULTS: Of 28 MCI patients, 9 developed dementia due to AD, 2 developed frontotemporal dementia, and 1 developed moderate dementia of unknown etiology. The positive and negative predictive values and the accuracy of visual and fully automated analyses of (11)C-PiB for the prediction of progression to dementia due to AD were 0.50, 1.00, and 0.68, respectively, for the visual and 0.53, 1.00, and 0.71, respectively, for the automated analyses. Positive predictive value, negative predictive value, and accuracy of fully automated analyses of (18)F-FDG PET were 0.37, 0.78, and 0.50, respectively. Results of visual analyses were highly variable between raters but were superior to automated analyses. CONCLUSION: Both (18)F-FDG and (11)C-PiB imaging appear to be of limited use for predicting the progression from MCI to dementia due to AD in short-term follow-up, irrespective of the strategy of analysis. On the other hand, amyloid PET is extremely useful to rule out underlying AD. The findings of the present study favor a fully automated method of analysis for (11)C-PiB assessments and a visual analysis by experts for (18)F-FDG assessments.
Authors: Magda Bucholc; Xuemei Ding; Haiying Wang; David H Glass; Hui Wang; Girijesh Prasad; Liam P Maguire; Anthony J Bjourson; Paula L McClean; Stephen Todd; David P Finn; KongFatt Wong-Lin Journal: Expert Syst Appl Date: 2019-04-10 Impact factor: 6.954
Authors: Lars Frings; Sabine Hellwig; Tobias Bormann; Timo S Spehl; Ralph Buchert; Philipp T Meyer Journal: Eur J Nucl Med Mol Imaging Date: 2018-03-15 Impact factor: 9.236
Authors: Jae Myeong Kang; Jun-Young Lee; Yu Kyeong Kim; Bo Kyung Sohn; Min Soo Byun; Ji Eun Choi; Soo Kyung Son; Hyung-Jun Im; Jae-Hoon Lee; Young Hoon Ryu; Dong Young Lee Journal: Mol Diagn Ther Date: 2018-08 Impact factor: 4.074
Authors: Ian R Macdonald; Selena P Maxwell; George A Reid; Meghan K Cash; Drew R DeBay; Sultan Darvesh Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472